Midazolam

Evidence Level: L3

Predicted Indications: 1

Midazolam

Pharmacist Assessment Report

Midazolam: From Anxiety to Insomnia

One-Sentence Summary

Midazolam is a short-acting benzodiazepine, originally used for anxiety and sedation. The TxGNN model predicts it may be effective for insomnia, with 2 clinical trials (both only indirectly relevant) and 10 publications (several directly studying oral midazolam as a hypnotic) currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Anxiety
Predicted New Indication	Insomnia
TxGNN Prediction Score	0.9974
Evidence Level	L3
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled record. Based on the known pharmacology of the class, midazolam is a short-acting benzodiazepine that enhances GABA-A receptor-mediated inhibitory neurotransmission, producing sedative-hypnotic effects.

This mechanism is shared with approved benzodiazepine hypnotics such as flurazepam and triazolam. Anxiety and insomnia often occur together and both respond to enhanced inhibitory signalling, so the biological link is plausible.

Oral midazolam has also been studied, and in some countries used, as a hypnotic. The prediction is therefore closer to the rediscovery of an existing use than a novel repurposing. The very high TxGNN score is a computational prediction and does not replace clinical evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02142595	Phase 4	Completed	111	Dexmedetomidine vs midazolam sedation with spinal anaesthesia: postoperative sleep quality after transurethral prostatic resection. Midazolam was the comparator, in a perioperative setting rather than chronic insomnia
NCT00886314	Not applicable	Unknown	80	Clown doctors vs sedative premedication for preoperative anxiety in children. Not related to insomnia

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2121802	1990	Randomized, double-blind, multicenter trial	J Clin Psychopharmacol	Flurazepam vs midazolam over 14 days in chronic insomniacs, assessing sleep, performance and mood
2229461	1990	Multicenter clinical trial	J Clin Psychopharmacol	Executive summary of the 14-day flurazepam vs midazolam study in chronic insomniacs (sleep, performance, plasma levels)
6138072	1983	Double-blind trial	Br J Clin Pharmacol	Midazolam 15 mg vs Vesparax in 30 patients with insomnia secondary to neuromuscular disease. Both were effective hypnotics, and midazolam was better tolerated without hangover effects
6120704	1981	Dose-finding study	Arzneimittel-Forschung	Oral midazolam 10-30 mg in 75 hospitalized patients with mild to moderate secondary insomnia, establishing the optimal dose range
2883820	1986	Review	Acta Psychiatr Scand Suppl	Clinical use of hypnotics and the need for a variety of agents with differing pharmacokinetic profiles
17988972	2007	Review	Orv Hetil	Insomnia and cerebral hypoperfusion. General background, not midazolam-specific
36615100	2022	Pilot clinical study	J Clin Med	Lemborexant for insomnia and delirium prevention after endoscopic procedures. Midazolam is not the focus

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
135368	Mezolam 5mg Injection	Vial of 5 ml injection	Not specified
136398	Medistat 0.5mg Tablet	Strip of 1 tablet	Not specified
134770	Midazom 0.5 Nasal Spray	Bottle of 5 ml nasal spray	Not specified
140031	Megarest 5mg Injection	Vial of 5 ml injection	Not specified
133584	Midacip Nasal Spray	Packet of 5 ml nasal spray	Not specified

Twenty valid single-ingredient registrations are listed in total, covering injection, tablet and nasal spray forms.

Safety Considerations

Contraindications flagged in the knowledge graph (drug-disease associations, not label text): chronic obstructive pulmonary disease (including severe early-onset), cirrhosis of liver, angle-closure glaucoma, and chronic kidney disease (including chronic renal failure and end-stage renal failure).
Drug Interactions: 177 interactions were identified in total. Moderate-level examples include morphine, clarithromycin, cimetidine, ranitidine, omeprazole, bupropion, aprepitant, metoclopramide, miconazole, clotrimazole, dronabinol and nabilone. Minor-level examples include dexamethasone, betamethasone, magnesium oxide, aluminum hydroxide and calcium carbonate. Concomitant opioids and other central nervous system depressants warrant particular caution because of additive sedation and respiratory depression.

Package insert warnings were not available, so please refer to the package insert for the full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The supporting studies are mainly older (1981-1990) small trials of oral midazolam in secondary or chronic insomnia, and the two registered trials are only indirectly relevant. There is no recent Phase 3 evidence. The Indian registrations are mostly injectable and nasal forms, with no clear oral hypnotic presentation (a single tablet is listed, with no stated indication). The package insert safety review is still outstanding.

To proceed, the following is needed:

Package insert warnings and contraindications from the Indian regulatory source, as the safety screen cannot be completed without them
Mechanism of action data confirmed from DrugBank
Confirmation of which registered products and routes (especially oral) are suitable for a hypnotic use
Review of the full text of the older insomnia trials, and a comparison with currently approved hypnotics
A safety plan for patients with respiratory, hepatic or renal impairment, and for those on opioids or other central nervous system depressants
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.